Trial of Different Wound Dressings in Split-skin Grafted Third Degree Burns
Randomized-controlled Trial of Wound Healing, Pain, Microbiology, Handling and Thrift of Different Wound Dressings in Patients With Split-skin Grafted Third Degree Burns
1 other identifier
interventional
20
1 country
1
Brief Summary
In plastic and reconstructive surgery, treatment strategies of second-degree burn wounds and split-skin grafted third-degree burn wounds aim at reducing infection and improving reepithelialization. Although previous studies indicate that burn patients benefit from newer wound dressings, only a few studies comparing different wound dressings can be found. Therefore, the aim of this study is to evaluate time to reepithelialization, pain, microbiology, handling and costs of different wound dressings in patients with split-skin grafted third-degree burn wounds.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jul 2015
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2015
CompletedFirst Submitted
Initial submission to the registry
January 28, 2017
CompletedFirst Posted
Study publicly available on registry
September 17, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedFebruary 24, 2023
February 1, 2023
10.4 years
January 28, 2017
February 22, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Epithelialization
Percent of epithelialized area
through study completion, an average of 1 year
Secondary Outcomes (3)
Pain (on a visual analogue scale 0-10)
through study completion, an average of 1 year
Microbiologic Smear
through study completion, an average of 1 year
Subjective Handling
through study completion, an average of 1 year
Study Arms (4)
Device: Silver Nylon dressing
ACTIVE COMPARATOR1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
Device: Manuka-Honey
ACTIVE COMPARATOR1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
Device: Povidone-Iod (PVP-Iod)
ACTIVE COMPARATOR1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
Device: Hydrogel
ACTIVE COMPARATOR1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
Interventions
Non-staining Silver Nylon dressing with a permanently plated metallic surface on split-skin grafted third-degree burn wound
Manuka-Honey dressing on split-skin grafted third-degree burn wound
Povidone-Iod (PVP-Iod) dressing on split-skin grafted third-degree burn wound
Eligibility Criteria
You may qualify if:
- Consent-capable male and female patients
- ≥18 years of age
- ≥3% and ≤30% total body surface area (TBSA) split-skin grafted third-degree burn
- appropriate form of wound (not: too small) and localization (not: face, inplane surface)
- ability to asses pain
You may not qualify if:
- Immunosuppressive Therapy
- Clinical wound infection
- Allergy against porcine material, bee poison or honey, etherial oil, propyleneglycol, silver, nylon
- Relationship to someone who is involved in the study design or assessment
- Participation in other clinical trials
- Citizen of countries outside Europe
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Hospital Schleswig-Holsteinlead
- University of Luebeckcollaborator
Study Sites (1)
University of Schleswig-Holstein
Lübeck, Schleswig-Holstein, 23538, Germany
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Tobias Kisch, MD
University Hospital Schleswig-Holstein
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
January 28, 2017
First Posted
September 17, 2018
Study Start
July 1, 2015
Primary Completion
December 1, 2025
Study Completion
December 1, 2025
Last Updated
February 24, 2023
Record last verified: 2023-02
Data Sharing
- IPD Sharing
- Will not share